Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

Abstract: The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.

Abstract: A device including a material including halide perovskite nanocrystals forming a film and configured to receive first electromagnetic radiation having a first wavelength emitted by an excitation source, the first electromagnetic radiation is modulated to include information prior to being received by the material, the material is configured to absorb the first electromagnetic radiation including the information and to emit second electromagnetic radiation having a second wavelength and also including the information, the second wavelength being in the visible range, and the first wavelength of the first electromagnetic radiation is shorter than the visible range; a detector configured to receive the second electromagnetic radiation and to extract the information; and a screen connected to the detector and configured to display the information.

Abstract: Embodiments of the present disclosure provide devices and systems including a halide perovskite and/or phosphor to produce and/or communicate using visible light, and the like.

Abstract: Embodiments of the present disclosure provide devices and systems including a halide perovskite and/or phosphor to produce and/or communicate using visible light, and the like.

Abstract: A system and method are provided for indoor agriculture using at least one growth chamber illuminated by laser light. In an example embodiment of the agriculture system, a growth chamber is provided having one or more walls defining an interior portion of the growth chamber. The agriculture system may include a removable tray disposed within the interior portion of the growth chamber. The agriculture system also includes a light source, which may be disposed outside the growth chamber. The one or more walls may include at least one aperture. The light source is configured to illuminate at least a part of the interior portion of the growth chamber. In embodiments in which the light source is disposed outside the growth chamber, the light source is configured to transmit the laser light to the interior portion of the growth chamber via the at least one aperture.

Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

Abstract: Embodiments of the present disclosure provide devices and systems including a material including a halide perovskite and/or phosphor to produce and/or communicate using visible light, and the like.

Abstract: Embodiments of the present disclosure provide devices and systems including a material including a halide perovskite and/or phosphor to produce and/or communicate using visible light, and the like.

Abstract: The present disclosure is a method comprising the steps of performing one or more nucleic-acid based assays to identify mutations present in the breast tissue acquired from the subject corresponding to a first test module and a second test module associated with detection of at least one predetermined mutation of one or more genes, wherein each test module is configured to provide a positive outcome corresponding to at least one predetermined mutation detected in the tissue or a negative outcome corresponding to absence of detectable predetermined mutation in the sample; and identifying the type of neoplasm of the breast tissue based upon the provided outcome of the both test modules. Preferably, the first test module is associated with detection of mutation in MED12 gene and/or RARA gene, while the second test module is associated with detection of mutation in FLNA gene, SETD2 gene and/or MLL2 gene.

Abstract: The present disclosure provides a method of assaying susceptibility and/or confirming diagnosis of breast fibroadenomas development in a human subject. Preferably, the method comprises the steps of performing a nucleic acid-based assay to analyze an isolated polynucleotide encoding at least exon 2 of MED12 gene from a sample acquired from the human subject; and regarding the human subject with greater susceptibility and/or confirming diagnosis of breast fibroadenomas development by detecting a mutation in the isolated polynucleotide. The mutation can be a splice site mutation located at position ?8 of exon 2 of the MED12 gene, a missense mutation located at codon 44 of cDNA of the MED12 gene or a missense mutation located at codon 36 of cDNA of the MED12 gene.

Abstract: The present invention is directed to methods for determining the activity of a promoter. The present invention further describes a method for determining the susceptibility of a subject to cancer and biomarkers for detecting cancer in a subject.

Abstract: A system and method are provided for indoor agriculture using at least one growth chamber illuminated by laser light. In an example embodiment of the agriculture system, a growth chamber is provided having one or more walls defining an interior portion of the growth chamber. The agriculture system may include a removable tray disposed within the interior portion of the growth chamber. The agriculture system also includes a light source, which may be disposed outside the growth chamber. The one or more walls may include at least one aperture. The light source is configured to illuminate at least a part of the interior portion of the growth chamber. In embodiments in which the light source is disposed outside the growth chamber, the light source is configured to transmit the laser light to the interior portion of the growth chamber via the at least one aperture.